Short answer: a CPSR has two parts — Part A documents what the product is and how a user is exposed to it; Part B is a qualified assessor's signed calculation and conclusion. Files are rejected for missing exposure data and unsupported assumptions, not for long prose.

No cosmetic may be placed on the EU market without a product information file, and the safety report is the part of that file a reviewer reads first. Brands often commission one late, after the formula and the artwork are fixed, and then discover that the exposure calculation assumed a use pattern that does not match the label.

This guide sets out what the two parts must contain, who is allowed to sign, where the assessment usually breaks, and how the report relates to the rest of the file that has to be kept for ten years.

Where the CPSR sits in the regulation

Under Regulation (EC) No 1223/2009, a cosmetic product placed on the EU market must have a product information file (PIF) held by the responsible person and, since the 2013 transition, notified through CPNP before it is placed on the market. Annex I sets out what the safety report must contain. The PIF must be kept for ten years after the last batch is placed on the market.

Three structural points follow, and they matter to a non-EU manufacturer:

  • The responsible person must be established in the EU. The manufacturer can supply data; the responsible person holds the file and the liability.
  • The CPSR is product-specific, not factory-specific. A GMP certificate supports the file; it does not replace the assessment.
  • The file is produced before launch, but updated after it. Formula changes, new use instructions, a new packaging material or a reported undesirable effect all trigger a review.

Part A: the information the assessment rests on

Part A is a dossier, not an opinion. Each section has an owner, and gaps here are the most common reason a file is sent back.

Section What it must contain Who supplies it
A1 Quantitative and qualitative composition Full formula, INCI names, percentages, function of each ingredient, and identification of the fragrance composition Brand and manufacturer
A2 Physical, chemical and stability characteristics Specification, stability data, compatibility with packaging material Manufacturer laboratory
A3 Microbiological quality Preservation strategy, challenge test result, microbiological specification Manufacturer laboratory
A4 Impurities, traces, information on packaging material Heavy-metal and impurity profile, plasticiser and migration data Manufacturer plus material suppliers
A5 Normal and reasonably foreseeable use Use instructions, frequency, amount per application, target population, exposure route Brand, based on label and claim
A6 Substance exposure Calculated exposure per ingredient per route, using a recognised model Assessor, with brand inputs
A7 Toxicological profile of substances Endpoint data and read-across for each ingredient Assessor
A8 Undesirable effects and serious undesirable effects Known data, complaint history where available Brand and manufacturer
A9 Product information Labelling, claims, any other relevant information Brand

The section that decides most disputes is A5. "Apply as needed" is not a use pattern; the assessment needs a defensible amount per application and a frequency, because everything in A6 is a function of those two numbers. A body lotion assessed at 5 g per application for a 60 kg adult gives a different margin of safety from one assessed at 15 g.

Part B: the calculation and the signature

Part B contains the assessor's reasoning and conclusion:

  • Assessment conclusion — whether the product is safe for its intended use, with any restrictions.
  • Labelling warnings and instructions — the warnings that the assessment assumes are present on the label.
  • Reasoning — the exposure calculation, the margin of safety for each ingredient of concern, the treatment of any CMR substance, and the consideration of vulnerable groups.
  • Assessor credentials and signature — name, qualification, date.

The margin of safety calculation is the core: systemic exposure dose is divided into the no-observed-adverse-effect level, and a margin of at least 100 is normally expected. Where an ingredient has no reliable NOAEL, the assessor has to say so and justify the alternative — and that justification is what a competent authority will examine if the product is ever queried.

Two things get signed off that brands overlook. The first is the packaging material: a formula assessed as safe in glass may not be assessed as safe in a plastic with an uncharacterised plasticiser. The second is the claim: a product claimed for use around the eyes has a different exposure assumption from a body product, and the assessment must match the artwork.

Who may sign

The assessor must hold a diploma or other evidence of formal qualification in pharmacy, toxicology, medicine, dermatology or a similar discipline, as set out in the regulation. In practice, most brands work with a qualified toxicologist or a pharmacy-qualified assessor who maintains a portfolio of product types.

The signature is not a formality. If the assessor has not seen the artwork, the packaging specification and the challenge test, the signature certifies assumptions rather than facts, and the file is weak at exactly the point a market surveillance authority would probe.

Where CPSR files actually fail

  • Exposure assumptions that do not match the label. A "generous application" body cream assessed at a face-cream dose is the classic mismatch.
  • Stability data too short for the claimed shelf life. A 36-month claim supported by three months of accelerated data needs a justification, not just a table.
  • Challenge test missing or failed. Preservation cannot be assumed from the preservative level; it has to be demonstrated.
  • Packaging compatibility untested. Migration from an uncharacterised plastic is a real gap, not a theoretical one.
  • Fragrance composition undisclosed. The assessor needs the fragrance breakdown, not just "parfum".
  • Nanomaterials or CMR substances without the specific annex treatment. These require additional data and, in some cases, notification.
  • A generic report reused across products. Multi-product PDFs with a changed cover page do not survive scrutiny.

Our stability testing guide and preservative challenge explainer cover the two data sets that most often arrive incomplete.

Timelines and what drives them

A complete CPSR for a straightforward leave-on emulsion typically takes two to four weeks once the formula, stability data, challenge test and packaging specification are available. The gating item is rarely the assessor; it is the data package. Files that take three months usually spent ten weeks waiting for a fragrance breakdown or a packaging migration statement.

Budget-wise, the report is a small fraction of a launch, but it is the item that blocks CPNP notification, and CPNP notification blocks sale. Sequencing it after artwork approval is a common and expensive mistake: artwork changes that follow the assessment force the assessment to be reissued.

The most repeated misconception

The most common statement we hear is that "the CPSR is a one-time document". It is not. The responsible person must keep it up to date, and the regulation requires review when there is a change in formula, packaging, use or in the toxicological knowledge of an ingredient. A file that has not been reviewed since 2021 is not a compliant file for a 2026 product even if the formula has not changed, because the ingredient data may have.

What the manufacturer can hand over

A Chinese manufacturer can supply the parts of Part A that belong to production: quantitative formula, specifications, stability data, challenge test, microbiological specification, heavy-metal and impurity results, and packaging material specifications. It cannot act as the EU responsible person or sign the assessment. Our batch documentation guide lists what travels with each shipment, and our EU regulation 2026/909 summary covers the ingredient restrictions that most often force a CPSR revision.

FAQ

Q: Can a CPSR cover a product family with several shades? A: Only where the shades share a base and differ solely in colourants within assessed limits, and the assessor must state that basis explicitly. A different fragrance or a different active means a separate assessment.

Q: Does the safety assessor need to be based in the EU? A: The responsible person must be established in the EU; the assessor must hold a recognised qualification. Many brands use an EU-based assessor because it simplifies file holding and communication with authorities.

Q: How long must the product information file be kept? A: Ten years after the last batch is placed on the market, held by the responsible person and available to competent authorities on request.

Q: Is a challenge test required for an anhydrous product? A: An anhydrous product with no water activity may not need a full challenge test, but the assessor must justify that position in Part A. The justification, not the exemption, is what gets reviewed.

Q: What triggers a CPSR update after launch? A: A formula change, a packaging material change, a new use instruction or claim, a reported serious undesirable effect, or new toxicological information on an ingredient. Any of these requires a documented review.